3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Hepatoblastoma
2
Glioblastoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Ototoxicity
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Vorinostat
×
1 year
×
Clear all
No trials found.